The Factors That May Predict Response to Rituximab Therapy in Recurrent Focal Segmental Glomerulosclerosis: A Systematic Review

Table 1

Demographic characteristics of renal transplant patients with recurrence FSGS that received rituximab. Values expressed as median (range) or proportion (%).

Variable	Results
Age at diagnosis (years)	6 (1–40)
Age at transplant (years)	18 (5–48)
Time to end stage renal disease (years)	3 (0.16–19)
Recipient male	22/39 (56.4)
Deceased donor transplant	26/39 (66.7)
Time to relapse of FSGS (days)	3 (1–3513)
Serum albumin at relapse (g/dL)	2.5 (1.2–4.4)
Proteinuria at relapse (g/day)	6.2 (1.1–97.4)
Diagnosis of PTLD	3/39 (7.7)
Number of plasmapheresis treatments	21 (0–133)
Number of rituximab doses	4 (1–6)
Complete response to therapy	17/39 (43.5)
Time to response from rituximab (months)	2 (0.63–12)